LumiraDx Limited (LMDX): Price and Financial Metrics


LumiraDx Limited (LMDX): $1.03

0.03 (+3.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LMDX Stock Price Chart Interactive Chart >

Price chart for LMDX

LMDX Price/Volume Stats

Current price $1.03 52-week high $11.09
Prev. close $1.00 52-week low $0.93
Day low $0.94 Volume 342,500
Day high $1.03 Avg. volume 300,834
50-day MA $1.40 Dividend yield N/A
200-day MA $4.66 Market Cap 46.60M

LumiraDx Limited (LMDX) Company Bio


LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018. LumiraDx Limited was incorporated in 2002 and is based in London, the United Kingdom.


LMDX Latest News Stream


Event/Time News Detail
Loading, please wait...

LMDX Latest Social Stream


Loading social stream, please wait...

View Full LMDX Social Stream

Latest LMDX News From Around the Web

Below are the latest news stories about LUMIRADX LTD that investors may wish to consider to help them evaluate LMDX as an investment opportunity.

LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic”LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Today, LumiraDx Limited (Nasdaq: LMDX) a next-generation point of care diagnostics company, in partnership the British In Vitro Diagnostics Association, released the Testing Times report which outlines the role of rapid diagnostics in tackling antimicrobial resistance (AMR)

Yahoo | September 22, 2022

Bullish LumiraDx Limited (NASDAQ:LMDX) investors are yet to receive a pay off on their US$10m bet

Insiders who bought US$10m worth of LumiraDx Limited's ( NASDAQ:LMDX ) stock at an average buy price of US$1.74 over...

Yahoo | September 16, 2022

Analysts Have Just Cut Their LumiraDx Limited (NASDAQ:LMDX) Revenue Estimates By 12%

The analysts covering LumiraDx Limited ( NASDAQ:LMDX ) delivered a dose of negativity to shareholders today, by making...

Yahoo | August 20, 2022

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and LumiraDx (LMDX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report) and LumiraDx (LMDX – Research Report) with bullish sentiments. Arcutis Biotherapeutics (ARQT) Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics today and set a price target of $57.00. The company's shares closed last Thursday at $25.99, close to its 52-week high of $26.14. According to TipRanks.

Howard Kim on TipRanks | August 19, 2022

Lower COVID-19 Testing Revenues Hit LumiraDx Q2, Plans Cost Cutting Initiatives

LumiraDx Limited's (NASDAQ: LMDX) Q2 FY22 sales reached $44.7 million compared to Q1 2022 revenue of $126.4 million and Q2 2021 revenue of $87.2 million, as COVID-19 moves from pandemic to the endemic stage. The analysts estimated sales of $53.09 million. Test strips on the LumiraDx Platform contributed revenues of $28 million, and Fast Lab Solutions' molecular reagents delivered $10 million, substantially from COVID-19 products. In response to lower COVID testing activity and to ensure efficien

Yahoo | August 18, 2022

Read More 'LMDX' Stories Here

LMDX Price Returns

1-mo -36.81%
3-mo -60.38%
6-mo -79.60%
1-year -86.41%
3-year N/A
5-year N/A
YTD -88.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4884 seconds.